KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Shares Repurchased (2018 - 2025)

Sarepta Therapeutics has reported Shares Repurchased over the past 9 years, most recently at $114.1 million for Q4 2025.

  • Quarterly results put Shares Repurchased at $114.1 million for Q4 2025, down 44.4% from a year ago — trailing twelve months through Dec 2025 was $218.6 million (down 38.41% YoY), and the annual figure for FY2025 was $139.1 million, down 32.2%.
  • Shares Repurchased for Q4 2025 was $114.1 million at Sarepta Therapeutics, up from $16.4 million in the prior quarter.
  • Over the last five years, Shares Repurchased for SRPT hit a ceiling of $205.1 million in Q4 2024 and a floor of -$136.7 million in Q4 2023.
  • Median Shares Repurchased over the past 5 years was $45.9 million (2024), compared with a mean of $46.0 million.
  • Biggest five-year swings in Shares Repurchased: skyrocketed 255.18% in 2022 and later plummeted 370.62% in 2023.
  • Sarepta Therapeutics' Shares Repurchased stood at $29.8 million in 2021, then skyrocketed by 69.6% to $50.5 million in 2022, then plummeted by 370.62% to -$136.7 million in 2023, then surged by 250.07% to $205.1 million in 2024, then crashed by 44.4% to $114.1 million in 2025.
  • The last three reported values for Shares Repurchased were $114.1 million (Q4 2025), $16.4 million (Q3 2025), and $41.6 million (Q2 2025) per Business Quant data.